about
Resolution of enantiomers of ketoprofen by HPLC: a review.High performance liquid chromatographic-mass spectrometric assay for the quantitation of BMS-204352 in dog K(3)EDTA plasma.Determination of lipoic acid in rat plasma by LC-MS/MS with electrospray ionization: assay development, validation and application to a pharamcokinetic study.HPLC method for determination of DRF-4367 in rat plasma: validation and its application to pharmacokinetics in Wistar rats.Quantitative determination of DRF-1042 in human plasma by HPLC: validation and application in clinical pharmacokinetics.Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard.Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection.Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analDetermination of rosuvastatin in rat plasma by HPLC: Validation and its application to pharmacokinetic studies.Development and validation of a sensitive ELISA for quantitation of Grastim (rhG-CSF) in rat plasma: Application to a pharmacokinetic study.Liquid chromatography/mass spectrometry for the quantitation of muraglitazar in monkey plasma.Simultaneous estimation of six anti-diabetic drugs--glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to hSimultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study.Validation of a simple HPLC method for DRF-4848, a novel COX-2 inhibitor suitable for pharmacokinetic application in rats.A rapid and highly sensitive method for the determination of glimepiride in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a pre-clinical pharmacokinetic study.Development and validation of a sensitive LC-MS/MS method with electrospray ionization using multiple ions for quantitation of torcetrapib in hamster and dog plasma.Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of rhein in human plasma: application to a pharmacokinetic study.Assessing the issue of instability due to Michael adduct formation in novel chemical entities possessing a carbon-carbon double bond during early drug development--applicability of common laboratory analytical protocols.Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I study.Measurement of xenobiotics in saliva: is saliva an attractive alternative matrix? Case studies and analytical perspectives.Clopidogrel: review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drug-drug interaction studies.Bioanalytical methods for the determination of itraconazole and hydroxyitraconazole: overview from clinical pharmacology, pharmacokinetic, pharmacodynamic and metabolism perspectives.Chiral bioanalysis of torcetrapib enantiomers in hamster plasma by normal-phase liquid chromatography and detection by atmospheric pressure chemical ionization tandem mass spectrometry.Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives.Highly sensitive method for the determination of a novel triple kinase inhibitor with anti-cancer activity, JI-101, in rat plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study.An overview of various validated HPLC and LC-MS/MS methods for quantitation of drugs in bile: challenges and considerations.Niacin and its metabolites: role of LC-MS/MS bioanalytical methods and update on clinical pharmacology. An overview.Highly sensitive method for the determination of JI-101, a multi-kinase inhibitor in human plasma and urine by LC-MS/MS-ESI: method validation and application to a clinical pharmacokinetic study.A strategy for extending the applicability of a validated plasma calibration curve to quantitative measurements in multiple tissue homogenate samples: a case study from a rat tissue distribution study of JI-101, a triple kinase inhibitor.Review of HPLC methods and HPLC methods with mass spectrometric detection for direct determination of aspirin with its metabolite(s) in various biological matrices.Quantification of fexofenadine in biological matrices: a review of bioanalytical methods.Concurrent determination of ezetimibe and its phase-I and II metabolites by HPLC with UV detection: quantitative application to various in vitro metabolic stability studies and for qualitative estimation in bile.Review of the quantitative analysis of cholesteryl ester transfer protein inhibitors.A concise review of the bioanalytical methods for the quantitation of sitagliptin, an important dipeptidyl peptidase-4 (DPP4) inhibitor, utilized for the characterization of the drug.Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine.A sensitive quantitative assay for the determination of propafenone and two metabolites, 5-hydroxypropafenone and N-depropylpropafenone, in human K2EDTA plasma using LC-MS/MS with ESI operated in positive mode.Area under the curve predictions of dalbavancin, a new lipoglycopeptide agent, using the end of intravenous infusion concentration data point by regression analyses such as linear, log-linear and power models.Sensitive and specific LC-ESI-MS/MS method for determination of ZYDPLA1, a novel long-acting dipeptidyl peptidase 4 inhibitor in rat plasma: An application for toxicokinetic study in rats.Review of HPLC and LC-MS/MS assays for the determination of various nonsteroidal anti-androgens used in the treatment of prostate cancer.Torcetrapib for animal and human pharmacokinetic studies: applicability of chiral and achiral methodologies.
P50
Q31022922-45205DE4-C969-4DF0-9CE6-3905C38ABDCDQ31046135-58C14129-33D1-4901-A8DB-F951CD80D3F9Q31114978-FDCA5A9C-73D6-4A32-BC47-47FB4EB914C4Q31115013-3C91B248-36A4-4BBE-AABF-23C456FDCA11Q31166562-148A97FD-24DF-4852-8427-A781FA241CA3Q31166680-5B47FE39-CE71-446C-A095-1DF7EC90193DQ33218819-1301FCA3-B129-4FF3-8CCF-8F22EE2BFAFFQ33222860-479F39ED-5144-44DC-BA4F-2B04AFE8A866Q33230714-56BC4495-1EA4-4833-8324-D1566E94E781Q33235001-1B18B0B5-C4EE-41B7-95AC-FCDBB8D530B2Q33235004-1787E0A9-2F66-4FBC-9E91-38B3968B9B13Q33235009-A2FEB734-7B51-4ED6-BD1F-40CBEF383DB9Q33250023-882ABDE1-EA58-417C-8717-4815B6B73272Q33258691-2491C3FD-B1F5-419A-9CDD-4CD2AFAECC71Q33291361-2D1C1A16-1A2D-4C7F-A22A-0AF58BD23D7BQ33308544-08CBB469-BD85-48E7-9698-7AE0C1AB9115Q33318502-5492969F-FF8A-4338-84F5-47B4097AE3C9Q33358241-3D72C2B8-67BE-4CC8-A10B-F245D0282B24Q33365479-0DE03278-DBEB-4870-86CF-F15D6ADB07AFQ33371845-4C4E41A3-08D8-4AA9-BD56-B526C33B7BE5Q33378137-9C0CBBCD-C784-4397-A21E-813AACEB8387Q33421192-AB69DE4B-E079-49C7-8960-71F4B1F06446Q33438651-74403E18-DDBC-460F-A529-E6958B69DF0EQ33512042-F7FDB1D5-9515-4EBA-848E-E3007EBBE99CQ33703980-F730C59D-8149-4450-B7EF-C70C5B608718Q33742355-CBAED5BC-0FAB-4320-B83A-A2E9DC2E9A6CQ33785060-65D832A5-5784-4148-B19B-03A1922664B3Q33905526-BB1E852F-7C16-4AF7-947E-ADE61FF339D2Q34005705-D1FA6773-FBBF-464F-9D24-F8E9CC919D57Q34148636-A2234327-130A-430F-984F-D460D817C803Q34166009-CA5EF1BE-3DDC-48B1-8CE3-90BE6D03D7B3Q34620302-4525F6F8-CABD-4835-A7DF-872C9D5C4871Q34708105-688C0C51-8A16-4C78-AC87-4CA01E04E615Q35923031-EE7C7A93-D305-46D0-BC00-3B2ACB4A2B3EQ36100847-1614AD67-6C47-453B-8FED-88F70D4121D6Q36297805-0B2E6AC2-9C2E-414F-99F6-E8E2B6D63139Q36307070-0389E00E-B48E-4D19-B225-27ED6A878D08Q36332490-967B102B-823B-4FF4-A9AD-AE5A9BD69E0EQ36411209-918A0726-48BF-4531-8B62-C15FD22E2453Q37810193-9EBD7149-AAC9-4AF4-9D15-92E2EB5E3FEE
P50
description
researcher
@en
wetenschapper
@nl
name
Nuggehally R Srinivas
@en
Nuggehally R Srinivas
@nl
type
label
Nuggehally R Srinivas
@en
Nuggehally R Srinivas
@nl
prefLabel
Nuggehally R Srinivas
@en
Nuggehally R Srinivas
@nl
P31
P496
0000-0002-5768-1332